Prognosis and Prognostic Factors in Patients With Idiopathic Dilated Cardiomyopathy in Japan  Results From a Nationwide Study

Miura, Katsuyuki; Matsumori, Akira; Nasermoaddeli, Ali; Soyama, Yoshiyuki; Morikawa, Yuko; Sakurai, Masaru; Kitabatake, Akira; Nagai, Masaki; Inaba, Yutaka; Nakagawa, Hideaki

doi:10.1253/circj.72.343

Cited by 23 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for this is that the available data were gathered quite a few years ago; the mortality rate findings also vary widely (from 6% to 43%). [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Moreover, apart from the score created by Miura et al based on a Japanese cohort from the 1990s, there is no prognostic model specific to mortality in DCM patients. 22 In addition, the Miura et al score was created in different therapy settings and has not been validated on a European DCM population.…”

Section: Introductionmentioning

confidence: 99%

Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy‐tailored prognostic model

et al. 2020

View full text Add to dashboard Cite

Aims The aims of this paper were to investigate the analytical performance of the nine prognostic scales commonly used in heart failure (HF), in patients with dilated cardiomyopathy (DCM), and to develop a unique prognostic model tailored to DCM patients. Methods and results The hospital and outpatient records of 406 DCM patients were retrospectively analysed. The information on patient status was gathered after 48.2 ± 32.0 months. Tests were carried out to ascertain the prognostic accuracy in DCM using some of the most frequently applied HF prognostic scales (Barcelona Bio-Heart Failure, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity, Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, Meta-Analysis Global Group in Chronic Heart Failure, MUerte Subita en Insuficiencia Cardiaca, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure, Seattle Heart Failure Model) and one dedicated to DCM, that of Miura et al. At follow-up, 70 DCM patients (17.2%) died. Most analysed scores substantially overestimated the mortality risk, especially in survivors. The prognostic accuracy of the scales were suboptimal, varying between 60% and 80%, with the best performance from Barcelona Bio-Heart Failure and Seattle Heart Failure Model for 1-5 year mortality [areas under the receiver operating curve 0.792-0.890 (95% confidence interval 0.725-0.918) and 0.764-0.808 (95% confidence interval 0.682-0.934), respectively].Based on our accumulated data, a self-developed DCM prognostic model was constructed. The model consists of age, gender, body mass index, symptoms duration, New York Heart Association class, diabetes mellitus, prior stroke, abnormal liver function, dyslipidaemia, left bundle branch block, left ventricle end-diastolic diameter, ejection fraction, N terminal pro brain natriuretic peptide, haemoglobin, estimated glomerular filtration rate, and pharmacological and resynchronisation therapy. This newly created prognostic model outperformed the analysed HF scales. Conclusions An analysis of various HF prognostic models found them to be suboptimal for DCM patients. A self-developed DCM prognostic model showed improved performance over the nine other models studied. However, further validation of the prognostic model in different DCM populations is required.

show abstract

Section: Introductionmentioning

confidence: 99%

Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy‐tailored prognostic model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These data suggested that hepatitis B and C virus may cause myocarditis and cardiomyopathies. Five variables, left ventricular dilatation, lower left ventricular ejection fraction, higher NYHA functional class, older age, and male sex were independently related to poor prognosis 17 .…”

Section: Burden Of Cardiomyopathies: Incidence and Prevalencementioning

confidence: 94%

“…Hepatitis B antibody was detected in 8.6% of dilated cardiomyopathy and 14.6% of hypertrophic cardiomyopathy patients. Hepatitis C antibody was present in 6.7% of dilated cardiomyopathy and 9.5% of hypertrophic cardiomyopathy patients 17 .…”

Section: Role Of Viruses In the Pathogenesis Of Cardiomyopathiesmentioning

confidence: 96%

Cardiac Involvement of Hepatitis B and C Virus Infection

Patwary¹,

Haque

Shoaib³

et al. 2013

Univ. Heart J.

View full text Add to dashboard Cite

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the cause of many different forms of heart disease worldwide and yet few cardiologists are aware of it as an etiology of heart disease, or its treatment. The burden of HBV and HCV derived heart diseases are global, with a higher prevalence in Asia, Africa, and low- and middle-income countries. The study showed that in more than 10% of Japanese patients, their cardiomyopathies are associated with HCV infection. More recently, it is found in the USA that up to 15% of patients with heart failure with myocarditis have been associated HCV infection. In contrast, in China 79% of patients with hepatocellular cancer and 37% of hepatitis C patients have heart disease, as detected by measuring a proven and sensitive biomarker of heart disease, NT-proBNP. In Pakistan, 17% of hepatitis C patients have heart diseases, as measured by this metric (NT-proBNP). Based on these data, 3% of 6.6 billion (198 million) persons worldwide are infected with HCV and 1737% (3473 million) persons are suffering from HCV-derived heart diseases. These figures may be comparable to the number of patients with hepatitis C. HCV infection causes only hepatitis in some patients, only heart diseases in some patients, and both hepatitis and heart diseases in other patients. A global network is required to establish methods to detect heart diseases caused by infectious agents. Other goals for the network are the expansion of preventive and therapeutic programs in under privileged countries. DOI: http://dx.doi.org/10.3329/uhj.v8i2.16084 University Heart Journal Vol. 8, No. 2, July 2012

show abstract

“…It was concluded that the nationwide survey revealed the present prognostic status of non-ischemic DCM in Japan and the 5 independent predictors of prognosis could be used in clinical practice as a predictive score. 54 As in the high score, the prognosis of end-stage nonischemic DCM is poor and heart transplantation or mechanical assist have been the only surgical procedures. However, the shortage of donors and the poor prognosis of mechanical assist devices means that non-transplant surgery for DCM with a non-ischemic etiology has been also reported since the 1990s.…”

Section: Non-ischemic Dcm and Lvrmentioning

confidence: 99%

Surgical Treatment for Heart Failure

Isomura

2009

Circ J

View full text Add to dashboard Cite

Congestive heart failure has become a major problem and the only surgical treatment for end-stage heart failure caused by dilated cardiomyopathy (DCM) had been heart transplantation. However, because of the shortage of donors, several procedures for non-transplant surgery have been developed. Published literature on left ventricular (LV) restoration was searched to review the new surgical procedures for treating patients with ischemic or non-ischemic DCM. LV restoration was initiated in the 1980s for repairing LV aneurysm. In the 1990s several surgical procedures were introduced for treating DCM, and the new evolving surgical treatment plays an important role in the management of DCM in the 21st century. (Circ J 2009; Suppl A: A-6 -A-12)

show abstract

Prognosis and Prognostic Factors in Patients With Idiopathic Dilated Cardiomyopathy in Japan Results From a Nationwide Study

Cited by 23 publications

References 16 publications

Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy‐tailored prognostic model

Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy‐tailored prognostic model

Cardiac Involvement of Hepatitis B and C Virus Infection

Surgical Treatment for Heart Failure

Contact Info

Product

Resources

About